Sharespot RSS feed | AIDS Education and Training Centers National Coordinating Resource Center (AETC NCRC)

Switching from TDF/FTC to TAF/FTC

Topic:

Publish Date:

Friday, March 18, 2016

Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with boosted PIs, 200/25 mg without boosters) or continued on TDF/FTC; the background third agents were not changed. At 48 weeks, 94.3% of TAF/FTC recipients and 93% of TDF/FTC recipients maintained HIV RNA suppression; the difference was not significant.

FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics

Topic:

Step 5: Effective Drug Treatment of HIV

Children (Newborn to 12 years)

Antiretroviral Therapy

Pharmacologic Topics

Publish Date:

Friday, March 18, 2016

The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.

It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute (switch) regimen for persons who are on a first ART regimen with sustained HIV suppression and no resistance mutations to the ARV components. Recommended dosage is 1 tablet once daily. As with Complera, it must be taken with a meal and cannot be taken concurrently with proton pump inhibitors.

Tissue Levels of TAF: Too Low for PrEP?

Topic:

Antiretroviral Therapy

Pharmacologic Topics

Pre-exposure Prophylaxis

Publish Date:

Thursday, March 17, 2016

A pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue and in anogenital fluid samples after administration of oral tenofovir alafenamide (TAF). This is of interest because administration of TAF (25 mg orally) results in 90% lower plasma concentrations of the TFV and TFV-DP than TDF, and 7-fold higher levels of TFV in mononuclear cells.

Tips for Successful Linkage to Care

Topic:

Step 3: Connecting HIV-Infected People to Quality HIV Care

Publish Date:

Thursday, February 4, 2016

I would like to start this new year introducing myself to the AIDS Education and Training Center (AETC) community. I had the pleasure of joining the AETC National Coordinating Resource Center (NCRC) as a Health Educator in December 2015. I look forward to using my skill set as a Certified Health Educator Specialist and seasoned patient navigator/linkage to care coordinator (LTCC) to provide a perspective based on direct interaction and delivery of care to clients from another standpoint in the healthcare team.

What’s Your QI IQ? - NQC Launches a National Quality Improvement Challenge

Topic:

Quality Improvement

Publish Date:

Tuesday, February 2, 2016

QI IQ image

Our understanding of quality in healthcare—how we talk about it and how we measure it—has evolved over time. However, the goal has remained the same: improving the health of people living with HIV. This means constantly challenging ourselves to do better. In essence, do quality improvement (QI) better.

Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression

Topic:

Step 5: Effective Drug Treatment of HIV

Antiretrovial Drug Treatment

Adolescents and Young Adults

Publish Date:

Thursday, October 1, 2015

The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg daily, to be taken with a meal, and of course in combination with other ARV medications.

Pyrimethamine Availability

Topic:

Step 5: Effective Drug Treatment of HIV

Antiretrovial Drug Treatment

Publish Date:

Thursday, October 1, 2015

Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click here).

TAF: New Data on Tenofovir Alafenamide Fumarate

Topic:

Antiretrovial Drug Treatment

Publish Date:

Thursday, October 1, 2015

Tenofovir alafenamide fumarate (TAF) is an investigational prodrug of tenofovir that in studies to date appears to have less renal and bone toxicity than the current tenofovir product, tenofovir disoproxil fumarate (TDF). This is because TAF is metabolized to tenofovir in lymphocytes and macrophages (as well as hepatocytes and some other cells), whereas TDF is converted to tenofovir in the blood. With TAF, levels of active tenofovir in plasma are about 90% lower, while levels in lymphocytes are higher.

START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV

Topic:

Antiretrovial Drug Treatment

Adherence

Antiretroviral Therapy

Basic Science

Drug Interactions

Initiating Treatment

Publish Date:

Thursday, October 1, 2015

The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and death and minimizing medication-related toxicity. Two large randomized controlled clinical trials, the START study and the TEMPRANO study, now demonstrate that earlier treatment with ART is most beneficial to boost immune recovery and prevent clinical events.

in+care Campaign Update: The Results are In

Topic:

Step 6: Treatment Success--Suppressed Viral Load

Publish Date:

Monday, September 28, 2015

in care National Quality Center (NQC) has completed its evaluation of the in+care Campaign -- the largest HIV quality improvement initiative carried out at the national level. We are pleased to announce that the Campaign demonstrated significant improvements in national retention and viral load suppression (VLS) performance.

Pages